Abstract:Chemokine receptor CCR2 is a member of the seven-transmembrane G-protein-coupled receptor superfamily, and is predominantly expressed on monocytes and macrophages. The interaction of the chemokine CCL2 with the CCR2 plays an important role in the recruitment of monocytes, natural killer cells, dendritic cells and T-lymphocytes. Recent studies have linked the CCL2/CCR2 axis to various inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, atherosclerosis, diabetes and even cancer. Thus, small molecule antagonists which can block the binding of CCR2 and CCL2 represent new therapeutic interventions of the inflammation-related diseases. By comprehensively analyzing the structures of the literature-reported potent CCR2 antagonists, we concluded a pharmacophore model for CCR2 inhibition, including a basic amino center, a hydrophobic aromatic ring on the right-hand side, and an amide group which serves as a hydrogen bond acceptor and a hydrogen bond donor. Then we performed the lead deconstruction and pharmacophore model-based privileged fragment reassembly strategy to discover new scaffold small molecule CCR2 inhibitors. The lead-like privileged scaffolds of alpha-alkyl-gamma-aminobutanamide and glycinamide were selected to combine with novel aromatic moiety and amide portion, delivering 3 classes of new structure CCR2 inhibitors. Total 11 compounds were designed and synthesized via a facile convergent synthetic procedure. The CCR2 antagonism activity evaluation revealed that N-(3-aminocyclopentane-carboxamido) methyl) benzamide was an active scaffold (exemplified by 1a, IC50= 25 nmol/L). The preliminary structure-activity relationship study indicated that the basic amino group and the lipophilic aliphatic moiety and small size aromatic group are important for the interaction with CCR2 protein. The replacement of the basic amino group with an amide would lead to the significant loss of the activity. This work provides a promising new structure CCR2 inhibitor and useful SAR conclusions which will promote the further development of CCR2 inhibitor into drug candidate.

Structure-based drug design using GPCR homology modeling: toward the discovery of novel selective CysLT2 antagonists.

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Pharmacophore identification, synthesis, and biological evaluation of carboxylated chalcone derivatives as CysLT1 antagonists.

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

Pharmacophore Model-based Design and Synthesis of New Structure Small Molecule CCR2 Inhibitors

A unique ligand-steered strategy for CC chemokine receptor 2 homology modeling to facilitate structure-based virtual screening

Structure-Based Virtual Screening of Ultra-Large Library Yields Potent Antagonists for a Lipid GPCR

Structure-Based Identification of Novel Ligands Targeting Multiple Sites Within A Chemokine-G-Protein-Coupled-Receptor Interface

Computational Studies of the Binding Modes of Ccr1 Antagonists

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Design and Synthesis of Tri‐substituted Chiral Pyrrolidin‐2‐one Derivatives As CCR4 Antagonists

Discovery of 1,5-Dihydro-4<i>H</i>-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2

Molecular Dynamics Insights into the Selectivity Toward CXCR1 and CXCR2 Antagonists

Synthesis, Structure–Activity Relationship Studies, and ADMET Properties of 3‐aminocyclohex‐2‐en‐1‐ones As Chemokine Receptor 2 (CXCR2) Antagonists

Identification of novel amino acid derived CCK-2R antagonists as potential antiulcer agent: homology modeling, design, synthesis, and pharmacology

3D-Pharmacophere Models for CC Chemokine Receptor 1 Antagonists.

Design, Synthesis, and Characterization of Novel CXCR4 Antagonists Featuring Cyclic Amines

Design, Synthesis, and Structure-Activity-relationship of a Novel Series of CXCR4 Antagonists.

Homology Modeling And Molecular Docking On Cck1 Receptor

Insights into binding modes of 5-HT2c receptor antagonists with ligand-based and receptor-based methods

Design, Synthesis, and Biological Characterization of a New Class of Symmetrical Polyamine-Based Small Molecule CXCR4 Antagonists.